Stockreport

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract...

Harrow, Inc.  (HROW) 
Last harrow, inc. earnings: 11/13 04:21 pm Check Earnings Report
PDF Topline Readout Expected in Q4 2024FDA Agrees to a MELT-300 Phase 3 Special Protocol Assessment NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”) [Read more]